VIA Pharmaceuticals stock analysis
VIA Pharmaceuticals (VIAP) Stock Price & Analysis
VIAP Stock Chart & Stats
- Day’s Range
- $0.01 - $0.02
- 52-Week Range
- $0.01 - $0.02
- Previous Close
- $0.01
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- $21
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- ―
- Beta
- 0.00
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
VIAP FAQ
What was VIA Pharmaceuticals’s price range in the past 12 months?
What is VIA Pharmaceuticals’s market cap?
When is VIA Pharmaceuticals’s upcoming earnings report date?
Is VIA Pharmaceuticals overvalued?
Does VIA Pharmaceuticals pay dividends?
What is VIA Pharmaceuticals’s EPS estimate?
How many shares outstanding does VIA Pharmaceuticals have?
Which hedge fund is a major shareholder of VIA Pharmaceuticals?
What is the TipRanks Smart Score and how is it calculated?
Company Description
VIA Pharmaceuticals
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Thomas Quertermous
- Employees
- 6
- Website
- www.viapharmaceuticals.com
- Address
- 750 Battery Street, San Francisco, CA, 94111, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 5 | 7 |
| Technical Analysis | 2 | 3 | 1 |
| Moving Averages | 2 | 2 | 6 |

